Valerie Herber
Psychiatric/Mental Health · Platteville, WINPI 1790186807
Payments from drug & device makers
Across 110 payments — averaging $19.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$326
- Lundbeck LLC$223
- AbbVie$221
- Neurocrine Biosciences, Inc.$216
- Johnson & Johnson$158
- Takeda Pharmaceuticals U.S.A., Inc.$153
- plus $868 from 11 others
What the payments were for
- Food & beverage$2,11898%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$107
How this compares
$2,165 in reported general payments places this provider in the 80th percentile of 384 psychiatric/mental health providers in Wisconsin.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 58 | $490,814 |
| VraylarCariprazine Hcl | 103 | $161,321 |
| AustedoDeutetrabenazine | 22 | $144,783 |
| AristadaAripiprazole Lauroxil | 22 | $69,208 |
| RexultiBrexpiprazole | 29 | $44,755 |
| TrintellixVortioxetine Hydrobromide | 39 | $31,678 |
| CaplytaLumateperone Tosylate | 17 | $26,812 |
| Invega SustennaPaliperidone Palmitate | 11 | $24,257 |
| LybalviOlanzapine/Samidorphan Malate | 15 | $22,567 |
| BelsomraSuvorexant | 49 | $21,287 |
| VyvanseLisdexamfetamine Dimesylate | 37 | $14,600 |
| FetzimaLevomilnacipran Hcl | 14 | $10,412 |
| Lisdexamfetamine Dimesylate | 54 | $10,312 |
| Aripiprazole | 108 | $9,903 |
| Lurasidone Hcl | 36 | $6,703 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $216 | $490,81458 claims |
| AbbVieVraylar, Fetzima | $221 | $171,733117 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $140 | $144,78322 claims |
| Alkermes, Inc.Aristada, Lybalvi | $326 | $91,77537 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $153 | $46,27876 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $152 | $44,75529 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $133 | $26,81217 claims |
| Johnson & JohnsonInvega Sustenna | $158 | $24,25711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 384 psychiatric/mental health providers in Wisconsin.
Other psychiatric/mental health in Platteville
- Noelle HebgenPlatteville$2K
- Carolyn DavidsonMilwaukee$46K
- Sherry AleksichMilwaukee$33K
- Bobbi DurstPewaukee$23K
- Ngozi ObioraMilwaukee$19K
- Glenda McConnellGreen Bay$14K
- Debra BenishekGreen Bay$12K
- Shalonda MylesBrown Deer$12K
- Victoria McGinleyMilwaukee$9K
- Janet BurnsBrookfield$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.